AstraZeneca announces availability of saxa / dapa FDC in UK
UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Pharmaceuticals